HC Wainwright Has Negative Outlook for PTGX Q2 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - HC Wainwright lowered their Q2 2025 EPS estimates for Protagonist Therapeutics in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.67) for the quarter, down from their prior forecast of ($0.65). HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at $0.93 EPS, FY2025 earnings at ($0.41) EPS, Q1 2026 earnings at $0.03 EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.41) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at $2.86 EPS.

A number of other analysts also recently weighed in on PTGX. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. BMO Capital Markets raised their price objective on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. The Goldman Sachs Group cut their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. JMP Securities reiterated a "market outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reissued an "outperform" rating and issued a $70.00 price objective on shares of Protagonist Therapeutics in a report on Friday, March 28th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $65.44.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX traded up $0.31 during midday trading on Monday, reaching $44.72. 95,020 shares of the company's stock were exchanged, compared to its average volume of 871,847. Protagonist Therapeutics has a 52-week low of $27.00 and a 52-week high of $60.60. The business's fifty day moving average price is $47.07 and its two-hundred day moving average price is $42.65. The stock has a market capitalization of $2.77 billion, a PE ratio of 16.87 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The firm had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.

Insider Buying and Selling

In related news, CFO Asif Ali sold 24,903 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the sale, the chief financial officer now directly owns 62,821 shares in the company, valued at $3,689,477.33. This trade represents a 28.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares in the company, valued at approximately $20,627,126.80. This represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,532 shares of company stock worth $3,665,786 in the last three months. 5.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. EFG Asset Management North America Corp. acquired a new stake in shares of Protagonist Therapeutics in the 1st quarter worth approximately $3,439,000. Checkpoint Capital L.P. acquired a new stake in Protagonist Therapeutics in the first quarter worth approximately $8,472,000. BVF Inc. IL lifted its position in Protagonist Therapeutics by 35.5% in the first quarter. BVF Inc. IL now owns 2,575,015 shares of the company's stock worth $124,528,000 after purchasing an additional 675,000 shares during the period. Advisors Asset Management Inc. boosted its stake in Protagonist Therapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,721 shares of the company's stock valued at $228,000 after purchasing an additional 2,123 shares in the last quarter. Finally, 683 Capital Management LLC increased its position in shares of Protagonist Therapeutics by 22.0% during the 1st quarter. 683 Capital Management LLC now owns 500,000 shares of the company's stock valued at $24,180,000 after purchasing an additional 90,000 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.